Evidence map›Paper›PMID 35211073›Full record

ArticleFrontiers in neurology2021

Efficacy and Safety of Tirofiban in Clinical Patients With Acute Ischemic Stroke.

Bin Han, Teng Ma, Zhendong Liu, Yiqun Wu, Weiwei Tan, Shaoyang Sun, Xuemei Li, Changyan Shao, Duyong Tang, Jinping Sun

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in neurology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 6 pooled it
6.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 6 syntheses or guidelines pooled it, 43 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. An Updated Review on Glycoprotein IIb/IIIa Inhibitors as Antiplatelet Agents: Basic and Clinical Perspectives.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2023
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 1 country.

Bin HanDepartment of Neurology, The Affiliated Hospital of Qingdao University, Qingdao, China.
Teng MaDepartment of Neurology, Qingdao Hospital of Traditional Chinese Medicine (Qingdao Hiser Hospital), Qingdao, China.
Zhendong LiuDepartment of Neurology, Laixi People's Hospital, Laixi, China.
Yiqun WuDepartment of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Center, Beijing, China.
Weiwei TanDepartment of Neurology, Pingdu People's Hospital, Pingdu, China.
Shaoyang SunDepartment of Neurology, The Affiliated Hospital of Qingdao University, Qingdao, China.
Xuemei LiDepartment of Neurology, Qingdao West Coast New Area Central Hospital, Qingdao, China.
Changyan ShaoDepartment of Pharmacology, Feixian People's Hospital, Linyi, China.
Duyong TangDepartment of Neurology, Pingdu Third People's Hospital, Pingdu, China.
Jinping SunDepartment of Neurology, The Affiliated Hospital of Qingdao University, Qingdao, China.
Qingdao University · CNAffiliated Hospital of Qingdao University · CNChengdu Third People's Hospital · CNPeking University · CNPingliang People's Hospital · CNQingdao Municipal Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIntravenous thrombolysis and endovascular thrombectomy have been approved for acute ischemic stroke (AIS). However, only a minority of patients received these treatments in China. We aimed to evaluate the efficacy and safety of tirofiban in patients with AIS who were not undergoing early recanalization treatments.

methodsPatients with mild-to-moderate stroke [National Institutes of Health Stroke Scale (NIHSS) score, 4-15] were enrolled in this study. Patients due to cardiogenic embolism were excluded. Eligible patients within 12 h from symptom onset were randomly assigned (1:1) to receive tirofiban (a loading dose of 0.4 μg/kg/min over 30 min and a maintenance dose of 0.1 μg/kg/min up to 48 h) followed by regular treatment or to receive regular treatment (aspirin at a dose of 100 mg per day for 90 days) (control). The primary outcome was the proportion of favorable functional outcomes at 90 days [defined as the modified Rankin Scale (mRS) score of 0-2]. The secondary outcomes included a shift in the distribution of the mRS scores at 90 days and the NIHSS score at 24 h and 7 days. The primary safety outcome was symptomatic intracranial hemorrhage (sICH) within 7 days after tirofiban treatment.

resultsA total of 380 eligible patients were randomly assigned to the tirofiban group (

conclusionOur trial supports that tirofiban was safe and effective and might be a remedial treatment for patients with AIS who did not receive recanalization treatments. CLINICAL

trial registrationhttp://www.chictr.org.cn/, identifier: ChiCTR2000031297.

Indexed as

acute ischemic stroke (AIS)clinical trialefficacy and safety assessmentmodified Rankin Scale (mRS) functional outcometirofiban

Identifiers

PMID35211073
PMCPMC8860815
OpenAlexW4210880583

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.